Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological…
Background: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma.
Objectives: To provide an overview of the management of the French Stage III melanoma population after complete lymph node resection prior to new adjuvant therapies.
- Ref: doi: 10.1684/ejd.2020.3848.
- Année de publication : 2020
- Auteurs : Dalle S, Varey E, Nguyen JM, Dupuy A, Montaudie H, Lesage C, Mortier L, Leccia MT, Skowron F, Celerier P, Meyer N, Dutriaux C, Dalac-Rat S, Khammari A, Lebbe C, Dréno B.
- Réseaux : Réseaux: « Immunothérapies » & « Hub Oncologie 4.0